Understand the source comparison
Best Peptides to Reduce Recovery Time Ranked: Efficacy Comparison
| Peptide | Primary Mechanism | Injury Type Efficacy | Typical Dose Range | Administration Route | Evidence Grade (A–D) | Professional Assessment ||—|—|—|—|—|—|| BPC-157 | VEGF upregulation, angiogenesis | Tendon, ligament, muscle, GI mucosa | 250–500 mcg dail
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Peptide | Primary Mechanism | Injury Type Efficacy | Typical Dose Range | Administration Route | Evidence Grade (A–D) | Professional Assessment ||—|—|—|—|—|—|| BPC-157 | VEGF upregulation, angiogenesis | Tendon, ligament, muscle, GI mucosa | 250–500 mcg daily | Subcutaneous (local or systemic) | B (animal models, case reports) | Strongest evidence for soft tissue; oral bioavailability unproven || TB-500 | Actin regulation, anti-fibrotic | Muscle tears, chronic inflammation | 2–5 mg twice weekly | Subcutaneous (systemic) | B (animal models, equine trials) | Best for diffuse injuries; reduces scar tissue formation || GHK-Cu | Copper delivery, collagen synthesis | Dermal wounds, connective tissue | 1–3 mg daily | Subcutaneous or topical | B (human dermal trials) | Age-dependent efficacy; declines in plasma with age || Thymalin | Immune modulation, anti-inflammatory | Systemic inflammation | 5–10 mg 2x weekly | Subcutaneous | C (limited human data) | Indirect recovery support; not tissue